Format

Send to

Choose Destination
Clin Mol Hepatol. 2016 Sep;22(3):339-349. Epub 2016 Sep 25.

Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B.

Author information

1
Department of Internal Medicine, Bundang Jesaeng Hospital, Seongnam, Korea.
2
Liver Center, Bundang Jesaeng Hospital, Seongnam, Korea.

Abstract

BACKGROUND/AIMS:

This study aimed to clarify the effect of obesity on the development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients receiving antiviral treatment.

METHODS:

This study applied a retrospective analysis to a historical cohort in Bundang Jesaeng Hospital. In total, 102 CHB patients were treated with entecavir as an initial treatment for CHB and checked for obesity using a body composition analyzer. Hepatic steatosis was measured semiquantitatively using Hamaguchi's scoring system in ultrasonography. Risk factors for the development of HCC were analyzed, including obesity-related factors (body mass index [BMI], waist circumference [WC], waist-to-hip ratio [WHR], visceral fat area [VFA], and hepatic steatosis).

RESULTS:

The median follow-up duration of the patients was 45.2 months (interquartile range: 36.0-58.3 months). The cumulative incidence rates of HCC at 1 year, 3 years, and 5 years were 0%, 5.3%, and 9.0%, respectively. Univariable analysis revealed that the risk factors for HCC development were a platelet count of <120,000 /mm2 (hazard ratio [HR]=5.21, P=0.031), HBeAg negativity (HR=5.61, P=0.039), and liver cirrhosis (HR=10.26, P=0.031). Multivariable analysis showed that the significant risk factor for HCC development was liver cirrhosis (HR=9.07, P=0.042). However, none of the obesity-related risk factors were significantly associated with HCC: BMI ≥25 kg/m2 (HR=0.90, P=0.894), WC ≥90 cm (HR=1.10, P=0.912), WHR ≥0.9 (HR=1.94, P=0.386), VFA ≥100 cm2 (HR=1.69, P=0.495), and hepatic steatosis (HR=0.57, P=0.602).

CONCLUSION:

HCC development is associated with liver cirrhosis but not obesity-related factors in CHB patients receiving entecavir.

KEYWORDS:

Antiviral treatment; Chronic hepatitis B; Hepatocellular carcinoma; Obesity

PMID:
27729627
PMCID:
PMC5066372
DOI:
10.3350/cmh.2016.0021
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Publishing M2Community Icon for PubMed Central
Loading ...
Support Center